GlassScriptPhysician profile
Lee P Shulman
NPI 1164447413
$558,561.48
in general payments reported to CMS, 2019-2025
26 companies · $128K in 2025
The $128K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $21K · 2021: $56K · 2022: $73K · 2023: $151K · 2024: $96K · 2025: $128K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $275K · Travel and Lodging: $38K · Consulting Fee: $34K · Honoraria: $15K · Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $274,587.50 |
| Travel and Lodging | $37,801.43 |
| Consulting Fee | $33,573.04 |
| Honoraria | $14,850.00 |
| Food and Beverage | $13,780.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $242,982.97 | 2021-2025 | |
| Astellas Pharma US INC | $67,418.35 | 2022-2025 | Veozah |
| Agile Therapeutics, INC. | $63,613.35 | 2021-2023 | Twirla |
| Daiichi Sankyo INC. | $59,068.72 | 2021-2024 | Injectafer |
| Aspira Women'S Health INC | $23,669.33 | 2019-2024 | Ova1 |
| Shield Therapeutics INC | $17,019.57 | 2022-2023 | Accrufer |
| Becton, Dickinson and Company | $15,651.11 | 2022-2023 | |
| Lupin INC. | $14,862.97 | 2019 | |
| Astellas Pharma Global Development | $11,610.31 | 2023-2025 | Veozah |
| Evofem Biosciences, INC. | $10,897.22 | 2021-2022 | |
| Mckesson Corporation | $5,215.00 | 2020 | |
| Scynexis, INC. | $5,044.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $4,714.71 | 2019-2025 | |
| Exeltis, USA INC. | $4,226.95 | 2024 | Slynd |
| Medicem INC. | $4,085.63 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $3,749.12 | 2019-2020 | |
| Coopersurgical, INC. | $2,773.49 | 2019-2023 | Paragard T 380a |
| Amag Pharmaceuticals, INC. | $818.97 | 2019 | |
| Abbvie INC. | $732.49 | 2022 | |
| American Regent | $146.62 | 2019-2023 | Injectafer |
| Myovant Sciences INC. | $109.02 | 2021-2022 | |
| Abbott Laboratories | $59.00 | 2019 | |
| Sumitomo Pharma America, INC. | $44.66 | 2024 | Myfembree |
| Allergan, INC. | $35.83 | 2019 | |
| Therapeuticsmd, INC. | $11.78 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Shulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.